Dr. Reddy’s Laboratories announced the conclusion of a United States Food & Drug Administration (USFDA) inspection at its formulations manufacturing facility in Bachupally, Hyderabad. The company was informed that the USFDA has classified the inspection outcome as ‘Voluntary Action Indicated’ (VAI). The inspection is now officially closed under the relevant regulations, signifying a resolution to the review process for this facility.
USFDA Inspection Concluded
Dr. Reddy’s Laboratories has received the outcome of a Good Manufacturing Practices (GMP) inspection conducted by the United States Food & Drug Administration (USFDA) at its formulations manufacturing facility, FTO-3, located in Bachupally, Hyderabad. The company was formally notified that the inspection has been classified as ‘Voluntary Action Indicated (VAI)‘.
Inspection Status
Following this classification, the USFDA has concluded that the inspection is officially closed. This development pertains to the facility’s compliance with regulatory standards and signifies the completion of the review process by the USFDA. The company provided this update on November 14, 2026.
Source: BSE
